RPTP Profile
Raptor Pharmaceutical Corp (RPTP) was a biopharmaceutical company that focused on the development of treatments for rare diseases. However, it's important to note that Raptor Pharmaceutical Corp is no longer an active publicly traded company.
The company was acquired by Horizon Pharma plc in 2016, and the combined entity now trades under the ticker symbol HZNP. At the time of the acquisition, the market capitalization of Raptor Pharmaceutical Corp was approximately $839 million.
Prior to the acquisition, Raptor Pharmaceutical Corp had developed a number of products for the treatment of rare diseases, including cystinosis, a genetic disorder that affects the kidneys and other organs. The company's lead product, Procysbi, was approved by the US Food and Drug Administration (FDA) in 2013 for the treatment of nephropathic cystinosis in children and adults.
Overall, while Raptor Pharmaceutical Corp is no longer an active publicly traded company, its legacy can be seen in the continued development and availability of its rare disease treatments by its successor, Horizon Pharma plc.
|
